Komori
Results6039Japan Animal Referral Medical Center Co.,Ltd.Information and Communications, Services and Others

Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)

For the interim period of the fiscal year ending March 2027, revenue, operating profit, ordinary profit and interim net income attributable to owners of the parent exceeded the year-earlier period, due to factors including an increase in the number of consultations and price revisions. The full-year earnings forecast and annual dividend forecast are unchanged from the latest published figures.

Worth reading
49Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
22.8
% (year-on-year change in operating income)
Wording
Conditional
How definitive the wording is.

Results for this period

Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAP
Net Sales3,367¥ millionYear on year +11.0%Progress 51.0%
Operating profit725¥ millionYear on year +22.8%Progress 57.1%
Ordinary income713¥ millionYear on year +21.0%Progress 58.4%
Net income attributable to owners of the parent489¥ millionYear on year +18.4%

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share¥37.86
Financial position at period-end
Total assets11,318¥ million
of which net assets 5,207 ¥ millionEquity ratio 46.0%vs. prior year-end +2.9pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Cash inflows and outflows
Operating+613,071
Investment-748,870
Financials-336,131
Net change-471,930

Stacked from zero: upward is an increase in cash, downward a decrease (in Thousand yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.

Cash and cash equivalents at end of period1,120,955 Thousand yen
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥6,600 million (YoY +6.6%)
Operating profit¥1,270 million (YoY +10.4%)
Ordinary income¥1,220 million (YoY +6.8%)
Profit attributable to owners of the parent¥890 million (YoY +6.8%)
Annual Dividend Forecast12 Yen → 13 Yen
Factors Behind Changes in Business Performance

The numbers of initial consultations, total consultations and surgeries increased as clinical capacity was strengthened, and the number of affiliated hospitals also rose. The number of rental contracts increased as a result of sales initiatives, while the benefit of higher revenue, the impact of price revisions in the previous fiscal year and ongoing productivity improvement initiatives contributed to profit.

Disclosure regarding the going concern assumption

Not applicable

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 Yes修正再表示 No
Changes in the scope of consolidationNo material changes (0 entities added or excluded)
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of fixed assets 826 Thousand yen / Extraordinary loss Loss on sale of non-current assets 45 Thousand yen
Depreciation and amortization240,140 Thousand yen
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors and analysts)
Issued Shares at Period-End14,391,000
Treasury Shares at Period-End1,465,940
Results for this period
ItemDetails
Fiscal Period ClassificationInterim period (second quarter)
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedConsolidated
Period Covered1 April 2026 to 30 September 2026
Net Sales¥3,367 million (YoY +11.0%)
Operating profit¥725 million (YoY +22.8%)
Ordinary income¥713 million (YoY +21.0%)
Profit attributable to owners of the parent¥489 million (YoY +18.4%)
Net income per share¥37.86
Equity ratioEnd of the current fiscal period 46 / End of previous period 43.1
Total assets¥11,318 million
Net assets¥5,207 million
Cash flows from operating activities613,071 Thousand yen
Cash flows from investing activities-748,870 Thousand yen
Cash flows from financing activities-336,131 Thousand yen
Cash and cash equivalents at end of period1,120,955 Thousand yen
Full-year earnings forecastNet Sales ¥6,600 million (YoY +6.6%) / Operating profit ¥1,270 million (YoY +10.4%) / Ordinary income ¥1,220 million (YoY +6.8%) / Profit attributable to owners of the parent ¥890 million (YoY +6.8%)
Annual Dividend Forecast12 Yen → 13 Yen
Depreciation and amortization240,140 Thousand yen
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of fixed assets 826 Thousand yen / Extraordinary loss Loss on sale of non-current assets 45 Thousand yen
Disclosure regarding the going concern assumptionNot applicable
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate Yes / Restatement No
Changes in the scope of consolidationNo material changes (0 entities added or excluded)
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors and analysts)
Issued Shares at Period-End14,391,000
Treasury Shares at Period-End1,465,940
Factors Behind Changes in Business PerformanceThe numbers of initial consultations, total consultations and surgeries increased as clinical capacity was strengthened, and the number of affiliated hospitals also rose. The number of rental contracts increased as a result of sales initiatives, while the benefit of higher revenue, the impact of price revisions in the previous fiscal year and ongoing productivity improvement initiatives contributed to profit.
Items this document does not state (10)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogImpairment lossMaterial subsequent events

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The number of consultations increased as clinical capacity was strengthened, while the number of rental contracts also increased as a result of sales initiatives. In addition to the benefit of higher revenue, the impact of price revisions implemented in the previous fiscal year and ongoing productivity improvement initiatives contributed to profit. A review of useful lives also increased operating profit and other items by ¥48.855 million.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated) | Japan Animal Referral Medical Center Co.,Ltd. (6039) timely disclosure | Komori